Condition: Advanced Pancreatic Ductal Adenocarcinoma · Sponsor: Sir Run Run Shaw Hospital
Icaritin is a drug that has been approved by the National Medical Products Administration (NMPA) based on a multicenter, randomized, double-blind, parallel-controlled Phase III clinical trial - SNG1705 ICR-1. It is used for patients with unresectable hepatocellular carcinoma who are not suitable for or refuse standard treatment and have not previously received systemic therapy. According to numerous studies, in tumor cells, Icaritin can downregulate the expression of TNF-α, IL-6, PD-L1 and exert anti-tumor effects. At the same time, it regulates the tumor immune microenvironment by reducing the secretion of TNFa and IL-6 as well as inhibiting PD-L1 expression through decreasing MDSC cell proportion. Importantly, Icaritin has excellent safety profile and greatly ensure patients' quality of life clinically. Rare grade 3-4 TRAEs were observed in clinical trials which is uncommon among existing standard drugs. Good safety is a prerequisite for combination therapy; therefore, further exploration of optimal drug combinations is worth considering. Thus,we investigated the efficacy and safety of Icaritin administered in conjunction with AG in patients newly diagnosed with advanced pancreatic ductal adenocarcinoma, compare with AG only.
This description comes directly from the study's public registry record.
Xiaolong Liu · 13588457667 · liuxiaolong@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Memorial Hospital | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Henan Provincial People's Hospital | Zhengzhou, Henan, China | Recruiting |
| Hubei Cancer Hospital | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Provincial People's Hospital | Changsha, Hunan, China | Not Yet Recruiting |
| Sir Run Run Shaw Hospital | Hangzhou, Zhejiang, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06825546